A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer-Reference-Cited by-同舟云学术

A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer

Published:2019-11 Issue: Volume:137 Page:136-143
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Besse Benjamin,Barlesi Fabrice,Demedts Ingel,Fuentes Pradera Jose,Robinet Gilles,Gazzah Anas,Soldatenkova Victoria,Frimodt-Moller Bente,Kim Jong Seok,Vansteenkiste Johan^ORCID

Funder

Eli Lilly and Company

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference22 articles.

1. Non–small cell lung cancer, version 5.2017;Ettinger;J. Compr. Canc. Netw.,2017

2. Systemic therapy for stage IV non–small-cell lung cancer: american society of clinical oncology clinical practice guideline update summary;Hanna;J. Oncol. Pract.,2017

3. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Planchard;Ann Oncol.,2018

4. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial;Thatcher;Lancet Oncol.,2015

5. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial;Pirker;Lancet,2009

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abemaciclib pharmacovigilance analysis：a real-world analysis of post-marketing surveillance Data;2023-04-07

2. Prognostic and immunological characteristics of CDK1 in lung adenocarcinoma: A systematic analysis;Frontiers in Oncology;2023-03-06

3. Role of ErbB1 in the Underlying Mechanism of Lapatinib-Induced Diarrhoea: A Review;BioMed Research International;2022-06-28

4. Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials;Clinical and Translational Oncology;2021-08-07

5. Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC;Frontiers in Oncology;2021-07-30